Premium
Assessment of cognition in early dementia
Author(s) -
Silverberg Nina B.,
Ryan Laurie M.,
Carrillo Maria C.,
Sperling Reisa,
Petersen Ronald C.,
Posner Holly B.,
Snyder Peter J.,
Hilsabeck Robin,
Gallagher Michela,
Raber Jacob,
Rizzo Albert,
Possin Katherine,
King Jonathan,
Kaye Jeffrey,
Ott Brian R.,
Albert Marilyn S.,
Wagster Molly V.,
Schinka John A.,
Cullum C. Munro,
Farias Sarah T.,
Balota David,
Rao Stephen,
Loewenstein David,
Budson Andrew E.,
Brandt Jason,
Manly Jennifer J.,
Barnes Lisa,
Strutt Adriana,
Gollan Tamar H.,
Ganguli Mary,
Babcock Debra,
Litvan Irene,
Kramer Joel H.,
Ferman Tanis J.
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.05.001
Subject(s) - dementia , cognition , psychology , disease , semantic memory , association (psychology) , cognitive psychology , medicine , neuroscience , pathology , psychotherapist
Better tools for assessing cognitive impairment in the early stages of Alzheimer's disease (AD) are required to enable diagnosis of the disease before substantial neurodegeneration has taken place and to allow for detection of subtle changes in the early stages of progression of the disease. The National Institute on Aging and the Alzheimer's Association convened a meeting to discuss state‐of‐the art methods for cognitive assessment, including computerized batteries, as well as new approaches in the pipeline. Speakers described research using novel tests of object recognition, spatial navigation, attentional control, semantic memory, semantic interference, prospective memory, false memory, and executive function as among the tools that could provide earlier identification of individuals with AD. In addition to early detection, there is a need for assessments that reflect real‐world situations so as to better assess functional disability. It is especially important to develop assessment tools that are useful in ethnically, culturally, and linguistically diverse populations as well as in individuals with neurodegenerative disease other than AD.